Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P35916
UPID:
VGFR3_HUMAN
Alternative names:
Fms-like tyrosine kinase 4; Tyrosine-protein kinase receptor FLT4
Alternative UPACC:
P35916; A8K6L4; B5A926; Q16067; Q86W07; Q86W08
Background:
Vascular endothelial growth factor receptor 3 (VEGFR-3), also known as Fms-like tyrosine kinase 4 (FLT4), plays a pivotal role in lymphangiogenesis and cardiovascular system development. It acts as a cell-surface receptor for VEGFC and VEGFD, promoting endothelial cell proliferation, survival, and migration. FLT4 signaling enhances VEGFC production, creating a feedback loop that amplifies its own signaling.
Therapeutic significance:
FLT4 is implicated in diseases such as Lymphatic malformation 1, characterized by lymphedema and hypoplasia of lymphatic vessels, and congenital heart defects. Understanding FLT4's role could lead to novel therapeutic strategies for these conditions, highlighting its importance in drug discovery.